Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease

Journal Title: 
British Journal of Haematology
Primary Author: 
Luzzatto L
Lucio Luzzatto, Anastasios Karadimitris
Original Publication Date: 
Sunday, November 1, 2020
Bone Marrow Disease(s): 

In the UK, early work on paroxysmal nocturnal haemoglobinuria (PNH) was conducted by John Dacie who, at the Hammersmith Hospital, first hypothesised that the PNH abnormality might arise through a somatic mutation; and who outlined with S.M. Lewis the relationship between PNH and aplastic anaemia. When the phosphatidylinositol glycan anchor biosynthesis Class A (PIGA) gene was identified by Taroh Kinoshita's group, jointly with him the Hammersmith group proved that PNH is caused in most patients by a single somatic mutation in the PIGA gene. At the same time, after Bruno Rotoli had spent a sabbatical at the Hammersmith, the 'immune escape model' for the pathogenesis of PNH was developed. Early this century, Peter Hillmen, formerly at the Hammersmith and now in Leeds, spearheaded the use of the complement-blocking (anti-C5) antibody eculizumab. This new medicine radically changed the management and the clinical course of patients with PNH. Recently a derivative of eculizumab with more favourable pharmacokinetics has been introduced. In view of the fact that these agents are associated with C3-dependent extravascular haemolysis, it is important that a number of inhibitors of the proximal complement pathway are now in the offing and may further improve the life of patients with PNH.